In the following video, Motley Fool health-care analyst David Williamson discusses Optimer's 10% jump on word that the company will look into "strategic alternatives" in the midst of its current difficult times. David speculates that this means the company may be looking to sell, and he discusses who some potential buyers might be.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report " 3 Stocks That Will Help You Retire Rich " names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Can Optimer Optimize Shareholder Returns? originally appeared on Fool.com.David Williamson owns shares of Pfizer. The Motley Fool recommends Cubist Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.